Endari FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
FDA Approved: Yes (First approved July 7, 2017)
Brand name: Endari
Generic name: L-glutamine
Dosage form: Oral Powder
Company: Emmaus Life Sciences Inc.
Treatment for: Sickle Cell Anemia
Endari (L-glutamine) is orally-administered pharmaceutical grade L-glutamine (PGLG), an amino acid formulation to relieve pain, swelling and other complications of sickle cell anemia.
Development timeline for Endari
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.